Provided by Tiger Fintech (Singapore) Pte. Ltd.

TransCode Therapeutics Inc.

9.94
-0.1100-1.09%
Post-market: 9.980.0400+0.40%19:09 EDT
Volume:35.54K
Turnover:339.68K
Market Cap:8.29M
PE:-0.02
High:10.38
Open:10.10
Low:9.02
Close:10.05
Loading ...

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Scientific Advisory Board to Drive RNA Oncology Advancements

Reuters
·
28 May

Transcode Therapeutics Appoints DR. Phillip D. Zamore to Science Advisory Board

THOMSON REUTERS
·
28 May

Transcode Therapeutics Inc trading halted, news pending

TIPRANKS
·
15 May

Transcode Therapeutics completes dosing of patients in Phase 1a cancer trial

TIPRANKS
·
08 May

Transcode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

THOMSON REUTERS
·
08 May

TransCode Therapeutics Faces Nasdaq Delisting Risk

TIPRANKS
·
08 May

TransCode Therapeutics Announces Reverse Stock Split

TIPRANKS
·
06 May

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

PR Newswire
·
06 May

Tyson Foods, Ford And 3 Stocks To Watch Heading Into Monday

Benzinga
·
05 May

BRIEF-Transcode Therapeutics Announces 1-For-28 Reverse Stock Split

Reuters
·
03 May

TransCode Therapeutics to Implement 1-for-28 Reverse Stock Split

MT Newswires Live
·
03 May

Transcode Therapeutics announces 1-for-28 reverse stock split

TIPRANKS
·
03 May

TransCode Therapeutics Approves 1-for-28 Reverse Stock Split to Meet Nasdaq Requirements

Reuters
·
03 May

Transcode Therapeutics Inc - Approves 1-for-28 Reverse Stock Split

THOMSON REUTERS
·
03 May

TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138

TIPRANKS
·
02 May

Transcode Therapeutics Inc - Two Patients Maintain Stable Disease for Seven Months

THOMSON REUTERS
·
01 May

Transcode Therapeutics Reports Further Progress on Phase 1a Clinical Trial With No Dose Limiting Toxicities Reported in Patients With Metastatic Cancer

THOMSON REUTERS
·
01 May

Transcode Therapeutics Inc - Ttx-Mc138 Well Tolerated at Highest Dose

THOMSON REUTERS
·
01 May

Transcode Therapeutics Inc - Pd Analysis Shows Mir-10B Target Engagement Post-Dosing

THOMSON REUTERS
·
01 May

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

PR Newswire
·
01 May